Clinical trials for BioNTech cancer vaccines should start this year in Britain: Ugur Sahin
"We believe that this should be possible for large amounts of patients before 2030," Sahin said.
Berlin: Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel.BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized...
Berlin: Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel.
BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said.
The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients.
"We believe that this should be possible for large amounts of patients before 2030," Sahin said.
Read also: BioNTech begins clinical trial of mRNA-based malaria vaccine candidate
The technology for this type of therapy has come a long way, he said.
"In 2014 we needed 3-6 months to create an individualized cancer vaccine, now we need 4-6 weeks. Our aim is to get it significantly under 4 weeks."
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd